Anti-Human VWF Reference Antibody (Caplacizumab, RUO)

Description: Caplacizumab (BS10626) is a research-grade recombinant antibody targeting von Willebrand antigen II. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: VH-VH
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 20 mM citric acid, 6.2% sucrose,0.01% Tween80
Concentration: 1.6mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: vonWillebrandantigenII,vonWillebrandfactor,F8VWF,vWF,VWF
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ALX-0081,PMP12A2h1-linkerAAA-PMP12A2h1,caplacizumab-yhdp,CAS:915810-67-2
Background: von Willebrand factor (VWF) is a ~309 kDa protein. Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Note: For research use only. Not suitable for clinical or therapeutic use.